Friedreich Ataxia
Conditions
Keywords
Friedreich ataxia, Resveratrol, Frataxin, Cardiomyopathy, Oxidative stress
Brief summary
The purpose of this study is to determine the effect of two doses of resveratrol taken for a 12 week period, on frataxin levels in individuals with Friedreich ataxia. This study will also measure the effect of resveratrol on markers of oxidative stress, clinical measures of ataxia, and cardiac parameters.
Detailed description
Resveratrol shows promise as an agent for the treatment of Friedreich ataxia due to its antioxidant properties, neuroprotective effects, and ability to increase frataxin levels in vitro and in vivo. This clinical pilot study aims to determine the effect of two doses of resveratrol (1g/day and 5g/day) taken for 12 weeks, on frataxin levels in individuals with Friedreich ataxia. Additional outcome measures include the effect of resveratrol on markers of oxidative stress, clinical measures of ataxia , and cardiac parameters (including relative wall thickness and left ventricular mass index).
Interventions
DRUGResveratrol
Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
Sponsors
Friedreich's Ataxia Research Alliance
Murdoch Childrens Research Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults with Friedreich ataxia due to homozygosity for the GAA repeat expansion in intron 1 of the FXN gene * Functional stage on the Ataxia subscale of the FARS of 1 or higher
Exclusion criteria
* Women who are pregnant or lactating * Active arrythmias or significant cardiac insufficiency * Use of idebenone, Coenzyme Q or vitamin E within 30 days prior to enrolment * Use of amiodarone or other medications which may have clinically significant drug interactions that cannot be safely monitored
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Lymphocyte frataxin level | 12 weeks | Change in lymphocyte frataxin levels at 12 weeks compared to baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Oxidative stress markers | 12 weeks | Oxidative stress, as measured by a) plasma F2-isoprostanes and b) urinary 8-hydroxyl-2-deoxyguanosine levels at 12 weeks compared to baseline |
| Clinical rating scales of ataxia | 12 weeks | Clinical rating scales of ataxia at 12 weeks will be compared to baseline. This will include: a) Friedreich Ataxia Rating Scale (FARS) b) International Cooperative Ataxia Rating Scale (ICARS) c) Scale for the Assessment and Rating of Ataxia (SARA) d) Friedreich Ataxia Functional Composite |
| Echocardiogram measures | 12 weeks | Changes in structural and functional 3D echocardiogram measures from baseline to 12 weeks will be reported |
| Pharmacokinetic studies of resveratrol | First 2 hours post dose | Pharmacokinetic data will be collected 45, 90 and 120 minutes after the first dose of resveratrol. Plasma concentration of resveratrol and its sulfate and glucuronide metabolites will be measured in ng/mL. |
Countries
Australia
Outcome results
None listed